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survey of headache in the United States. This study utilized data collected in the 2005 
baseline survey of 14,544 adults who were identiﬁ ed as having migraine based on
criteria proposed by the International Classiﬁ cation of Headache Disorders, 2nd
edition. Participants completed self-administered, validated questionnaires on head-
ache features, frequency, impairment, resource and medication use, and productivity
loss. Direct and indirect headache-related costs were estimated using unit-cost assump-
tions derived from the PharMetrics Patient-Centric database, wholesale acquisition 
costs of medications, and wage data from the US Bureau of Labor Statistics. The 
population of migraineurs was divided into quartiles (1–2, 3–6, 7–16, and 17–365
headache days) based on self-reported headache frequency in the past year. Analyses 
controlled for age, gender, income, geographic region, population density, and insur-
ance status. RESULTS: Of the original 14,544 identiﬁ ed migraine cases, 12,829 com-
pleted the 2005 survey and were included in this analysis. Higher headache frequency 
quartile was associated with more nights in hospital and increased visits to primary
care, urgent care, pain clinic, emergency room, and neurologists or headache special-
ists. The most commonly cited medications used for headache relief in all four quartiles
were non-prescription analgesics and NSAIDs, and the most commonly cited prescrip-
tion medications in all quartiles were the triptans. Lost productive time (but not
absenteeism) generally increased progressively in the higher quartiles. Average per-
person annual total costs, including direct and indirect costs, ranged from $2528 
(lowest quartile) to $6014 (highest quartile). CONCLUSIONS: Decreasing headache
frequency is associated with positive economic beneﬁ ts of reduced resource use and
productivity loss. These beneﬁ ts should be considered by stakeholders interested in 
improving migraine outcomes in a cost-effective fashion.
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OBJECTIVES: Examine the economic impact of generic substitution of the antiepi-
leptic drug (AED) topiramate in Canada; and convert observed Canadian costs into 
the settings of France, Germany, Italy, and the UK. METHODS: Health claims from
Québec’s provincial health plan (RAMQ) between January 2006 and September 2008 
were analyzed. Patients with epilepsy or non-febrile convulsions (ICD-9: 345, 780.3 
or 780.39) and q2 topiramate (Topamax) dispensings were selected. An open-cohort
design was used to classify patients’ observation into mutually-exclusive periods of 
branded versus generic use of topiramate. Total health care utilization and costs in 
Canada (C$2007/person-year) were compared between periods of branded versus 
generic use, after adjusting for demographics, treatment characteristics, and comor-
bidities. Annualized health care costs (€2007 and L2007/person-year) were converted
at the patient level using Canadian utilization rates, adjusted with service-use ratios 
and European unit costs. Non-parametric bootstrap procedure was used to determine
statistical signiﬁ cance for the cost measures. RESULTS: A total of 1164 patients (mean 
age: 39.8 years, 61.7% female) were observed for 2.6 years on average. Unadjusted 
results consistently associated generic use with signiﬁ cant increases in health care
resource utilization. Periods of generic topiramate use remained associated with sig-
niﬁ cant increases in pharmacy dispensings (other AEDs: 6%, non-AEDs: 31%, p 
.001), a 17% increase in hospitalizations (p  0.015), and 21% longer lengths of 
hospital stays (p  .001). Non-topiramate adjusted health care costs were C$1,060/
person-year higher during periods of generic use (p  0.005). Converted per-patient
health care costs excluding topiramate were estimated to be signiﬁ cantly higher for
generic relative to brand periods in all four countries (adjusted cost differences per 
person-year [95% CI]: France: €815 [€427–€1.215], Germany: €706 [€369–€1058], 
Italy: €795 [€430–€1177], UK: L485 [L283-L687]; p  0.001 for all comparisons).
CONCLUSIONS: Higher health care costs were projected for G4 European countries
from the Canadian experience following generic substitution of topiramate, offsetting 
potential savings from lower generic prices.
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OBJECTIVES: To evaluate the cost-effectiveness of using Apolipoprotein E (APOE)
testing and preventive treatment with Donepezil for Mild Cognitive Impairment (MCI)
patients and to consider various scenarios of positive gene distribution and treatment
strategies. METHODS: A decision tree was constructed to the costs and effects of the
intervention: an APOE predictive genetic test and preventive treatment with donepezil 
in the MCI population. Clinical data from a RCT conducted in North America 
between 1999–2004 were used for the model. This study concluded that donepezil
was associated with a lower rate of progression to Alzheimer’s Disease (AD) during 
the ﬁ rst 12 months of treatment in MCI patients, although the rate of progression to 
AD after three years was not lower among patients with donepezil than among those
given placebo. Our model examined several scenarios including different prevalence 
estimates for the APOE e 4 gene, a risk factor for developing AD and different treat-
ment strategies (with and without Donepezil). Extensive sensitivity analyses were 
performed on the probability of progressing to AD, health state utility and health care 
costs. RESULTS: Over 3 years preventive treatment of MCI patients is predicted to 
result in the gain of 0.015 QALYs, when comparing to usual care. The Incremental
cost was CAD $ 595 with donepezil treatment; consequently, the incremental cost-
effectiveness ratio (ICER) is estimated to be $81,599 when the APOE e 4 gene prob-
ability is 0.55. With a probability of 0.36, the average in developed countries, the
ICER is CAD $103,245. Results were less sensitive in the scenario with a lesser prob-
ability of APOE e 4. CONCLUSIONS: Genetic testing in combination with preventive 
donepezil treatment for MCI patients may not be economically attractive in this 
setting. Under certain assumptions, however, this intervention might be cost-effective 
for MCI patients due to delayed onset of AD.
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OBJECTIVES: Previous cost-effectiveness studies have modeled Alzheimer’s disease
(AD) progression in terms of cognitive function alone, a single global severity measure,
or progression to the need for “Full Time Care.” This study estimates AD progression 
in terms of correlated changes in cognition, behavior and function. These projections
are then used to analyze the cost-effectiveness of donepezil versus standard care in the
UK. METHODS: Patient-level data from eight randomized placebo-controlled done-
pezil trials and a seven-year follow-up registry provided the basis for modeling longi-
tudinal rates of change in cognition (MMSE), behavior (Neuropsychiatric Inventory), 
activities of daily living and Instrumental Activities of Daily Living. A discrete event 
simulation is used to project outcomes for two patient groups, identical except for
treatment: donepezil 10mg per day versus untreated. Patient mix and costs were 
developed from UK-speciﬁ c literature. Costs are reported in 2007 British pounds. The 
discount rate is 3.5%. RESULTS: After ten years, patients with mild to moderately 
severe AD (26 qMMSE q 10) on donepezil are better off than those without treatment,
with costs reduced from both health care system and societal perspectives, savings 
averaging a1421 and a4094 per patient respectively. Donepezil-treated patients experi-
ence 0.12 more QALYs per patient and their caregivers 0.01 QALYs compared to 
untreated patients and their carers. In sensitivity analyses, dominance holds over a 
wide range of inputs, including when treatment effects, the impact of disease severity 
on caregiver time and patient utility, and institutionalization rates are decreased by 
25%; or when the time horizon is decreased to 5 years. In probabilistic sensitivity 
analyses, donepezil dominates in 53 to 77% of replications (depending on perspective),
and results in cost/QALY estimates below a30,000 in 79 to 90% of replications. 
CONCLUSIONS: These results suggest that donepezil is highly cost-effective in 
patients with mild to moderately severe AD in the UK.
PND11
COST-EFFECTIVENESS OF SCREENING AND TREATMENT OF 
ALZHEIMER’S DISEASE WITH DONEPEZIL IN THE UNITED KINGDOM
Getsios D1, Blume S2, Ishak KJ3, MacLaine G4
1United BioSource Corporation, Concord, MA, USA, 2United BioSource Corporation, 
Bethesda, MD, USA, 3United BioSource Corporation, Montreal, QC, Canada, 4Eisai Europe 
Limited, Hatﬁ eld, Herthfordshire, UK
OBJECTIVES: The cost-effectiveness of screening adults presenting with subjective
memory complaints and treating those diagnosed with Alzheimer’s disease (AD) with 
donepezil 10 mg is examined for the UK. METHODS: Patient-level data from eight
randomized placebo-controlled donepezil trials and a seven-year follow-up registry 
were used to model correlated longitudinal rates of change and treatment effects in 
cognition, behavior, and function. Using UK AD prevalence and diagnosis patterns, a 
discrete event simulation projects outcomes for annual screening of patients aged over
65 reporting memory complaints, compared to no screening or donepezil treatment.
Patients with undiagnosed AD are assumed to report memory complaints between 
onset of the disease and the time they would have been diagnosed in the absence of 
screening (on average, 36 months from disease onset). RESULTS: Seventeen patients
need to be screened to diagnose one patient with AD. Screening costs average a5,100 
per patient diagnosed. Over a ten year time horizon, screening and treating reduces
total direct costs by an average of over a2,500 per diagnosed patient, and indirect costs 
by almost a4,500 per patient. QALYs gained with screening and donepezil treatment
average 0.17 per patient, compared to 0.12 QALYs per patient with donepezil treat-
ment when diagnosis is delayed in the absence of screening. QALY gains for caregivers 
are 0.02. In probabilistic sensitivity analyses, screening dominates no treatment in 31%
to 63% of replications (depending on perspective), and results in cost/QALY estimates
below a30,000 in 79% to 86% of replications. Overall, probabilistic analyses yielded 
a mean incremental cost-effectiveness ratio of a7,467/QALY if only direct costs were 
considered, and dominance from a societal perspective. CONCLUSIONS: Although 
screening has signiﬁ cant upfront costs, identifying and treating AD patients early results
in overall cost savings and QALY beneﬁ ts compared to no treatment, and larger QALY 
beneﬁ ts than treatment following delayed diagnosis without screening.
